Edesa Biotech, Inc.
(NASDAQ : EDSA)

( )
EDSA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.10%38.410.9%$1248.28m
JNJJohnson & Johnson -0.44%147.950.7%$870.62m
MRKMerck & Co., Inc. -0.06%80.970.7%$637.23m
ABBVAbbVie, Inc. -0.57%92.391.9%$603.09m
BMYBristol-Myers Squibb Co. 1.30%61.811.0%$599.18m
AZNAstraZeneca Plc -0.07%55.371.2%$573.33m
LLYEli Lilly & Co. 0.07%153.031.1%$425.60m
NVSNovartis AG -0.64%82.380.2%$142.36m
GSKGlaxoSmithKline Plc 0.39%40.950.2%$136.09m
MISTMilestone Pharmaceuticals, Inc. -3.27%9.480.0%$135.86m
OPKOPKO Health, Inc. -3.02%5.4611.2%$129.82m
NVONovo Nordisk A/S -0.02%64.630.1%$69.68m
RGENRepligen Corp. -3.25%147.817.2%$68.38m
PRNBPrincipia Biopharma, Inc. -7.86%84.670.0%$58.39m
SNYSanofi -1.17%50.910.2%$56.54m

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.